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AIDS, a disease previously associated with rapid 
death, has become a chronic illness in the developed 
world. Nucleoside reverse transcriptase inhibitors (NRTIs) 
in combinations with other antiretrovirals (highly active 
antiretroviral therapy, HAART) are the cornerstones of 
AIDS therapy, turning HIV infection into a manageable 
clinical entity. Life expectancy with HIV in well-resourced 
countries is now estimated to be up to two-thirds that of 
the general population [1]. 
Despite the incidence of most neurological 
complications of HIV has fallen with the introduction 
of effective therapy, therapeutic experience revealed 
serious side effects. Rates of sensory neuropathy (SN) 
have been rising since the first effective antiretroviral 
drugs were developed [2], and the associated pain has 
a major impact on quality of life. HIV-SN is comprised 
of at least two clinically indistinguishable, and often 
coexisting, neuropathies: a distal sensory polyneuropathy 
associated with HIV disease itself, and a distal sensory 
polyneuropathy associated with antiretroviral treatment, 
mainly with potentially neurotoxic NRTIs [3]. Recent 
studies suggest symptomatic SN prevalence rates of 
20% to 57% among ambulatory patients with HIV and 
the prevalence of pain has been reported as high as 50% 
to 90% [4]. Despite this high rate of pain, treatment of 
painful HIV-SN is often poor since analgesics used in 
other forms of neuropathic pain have proven ineffective 
[5]. Adding to the complexity, terminating NRTI therapy 
does not always reverse neuropathy and patients continue 
to suffer from pain, leading the antiretroviral neuropathic 
pain to become a major impact on quality of life in 
otherwise largely healthy individuals. With the high global 
HIV prevalence, and with infected individuals gaining 
increased access to HAART, painful HIV-SN represents a 
large and expanding world health problem. 
With this is mind, Sanna et al. [6] investigated 
the signalling pathways involved in the onset and 
development of the antiretroviral pain hypersensitivity 
to identify effective pain management strategies to limit 
discontinuation or abandon of antiretroviral therapy. 
Increases in BDNF concentrations in the dorsal horn of 
mice exposed to NRTI represent one of the early events, 
detected since a few hours after treatment, and this 
BDNF rise was correlated with pain hypersensitivity 
and allodynia [6]. However, BDNF influences different 
neuronal functions. After peripheral nerve damage it 
contributes to the pathogenesis of neuropathic pain and 
also activates a regenerative response to the axonal 
damage [7]. This dual effect makes targeting neurotrophin 
for the relief of neuropathic pain an approach that may 
have important safety limitations. Clinical studies of 
anti-BDNF antibodies for the relief of neuropathic pain 
conditions are lacking. However, unfavourable side effects 
emerged during the early phase clinical trials of anti-NGF 
antibodies and, due to these safety concerns, the United 
States Food and Drug Administration (FDA) placed all 
ongoing clinical trials on clinical hold. 
Elucidation of the early events in the signalling 
pathways downstream BNDF would allow to identify 
a more suitable therapeutic target to counteract the 
pronociceptive pathway leaving the regenerative response 
unaltered, thus reducing the incidence of untoward side 
effects. Increasing body of evidence suggests that the 
c-Jun N-terminal kinase (JNK) cascade is a critical 
signalling pathway for the onset and the maintenance 
of neuropathic pain. Sanna et al. [6] reported a robust 
overphosphorylation of both JNK1 and JNK2 isoforms 
since day 1 post antiretroviral injection in the spinal cord 
dorsal horn, along with a JNK-dependent increase in the 
phosphorylation of c-Jun, a transcription factor substrate 
of JNK involved in pain perception. In addition to c-Jun, 
identified transcription factors implicated in the sensory 
neuron response to axonal injury include activating 
transcription factor 3 (ATF3), widely known as marker 
of neurodegeneration. Co-immunoprecipitation results 
indicated that ATF3 and c-Jun can act together to regulate 
transcription through heterodimerization and that their 
coincident upregulation may act synergistically to induce 
neuropathic pain. 
Sanna et al. [6] showed that treatment with a JNK 
blocker prevented antiretroviral hyperalgesia by restoring 
the baseline or normal pain threshold of the neuropathic 
mice. Particularly relevant is that JNK inhibition prevents 
the onset and development of neuropathic pain since 
effective only when occurred before exposition to the 
neurotoxic antiretroviral. When the neuropathic pain is 
already established, the JNK blocker was ineffective. 
A JNK pathway blockade, instead of diminishing 
the stimulus-dependent response, would prevent that 
response and a JNK blocker could thus be used as 
prophylactic therapy to be administered before beginning 
the antiretroviral therapy to prevent the development of 
painful SN.
With an estimated 33 million people living with 
HIV and more gaining access to antiretroviral therapy 
every day, the management of antiretroviral associated 
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neuropathic pain is a problem of major global significance. 
Despite the decreased use in developed countries due 
to neurotoxicity, NRTIs remain in the first-line HIV 
treatment in many resource-limited countries as a result of 
its high effectiveness and inexpensiveness. Nevertheless, 
NRTI-induced neuropathy may precipitate abbreviation or 
discontinuation of antiretroviral therapy thus limiting viral 
suppression strategies. Authors [6] indicate JNK as a target 
to be exploited as a therapeutic approach to intervene and 
better manage the antiretroviral-induced neuropathic pain. 
The efficacy of JNK inhibitors to prevent the development 
of neuropathic pain might represent a unique preventive 
therapy that might enlarge and prolong the clinical use of 
these highly effective antiviral drugs, otherwise destined 
to be phased it out. JNK blockers are currently tested for 
clinical use for the treatment of several pathologies with 
a good tolerability profile and may represent a concrete 
therapeutic opportunity in humans.
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